Related Experiment Video
Updated: May 24, 2026
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Comparative activity of carbapenem testing (the COMPACT study) in Turkey
Hakan Leblebicioglu1, Nedim Cakir, Mustafa Celen
1Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey. hakanomu@omu.edu.tr
Background:
Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.
Methods:
Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.
Results:
Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.
Conclusions:
Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.
Insights
Doripenem demonstrated comparable or superior in vitro activity against Gram-negative pathogens compared to meropenem and imipenem in Turkish hospitals. This finding is crucial for guiding antibiotic selection in treating serious hospital-acquired infections.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Gram-negative bacterial infections, including Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are significant causes of hospital-acquired infections.
- Carbapenem antibiotics are vital for treating these infections, necessitating ongoing surveillance of their efficacy.
Purpose of the Study:
- To evaluate the in vitro activity of doripenem against Gram-negative clinical isolates in Turkey.
- To compare doripenem's efficacy with other carbapenems like meropenem and imipenem.
Main Methods:
- Ten centers in Turkey collected Gram-negative isolates from patients with various severe infections between May and October 2008.
- Isolate susceptibility testing was performed using E-test, with central laboratory confirmation and quality control.
Main Results:
- Doripenem exhibited MIC90 values of 32 mg/L for Pseudomonas spp., 0.12 mg/L for Enterobacteriaceae, and ≥64 mg/L for other Gram-negative isolates.
- Compared to meropenem and imipenem, doripenem showed similar or better activity across the tested Gram-negative pathogens.
- Higher MIC90 values were observed for intensive care unit (ICU) isolates compared to non-ICU isolates.
Conclusions:
- Doripenem demonstrated favorable in vitro activity against Gram-negative pathogens in Turkey.
- Doripenem showed comparable or superior efficacy to meropenem and imipenem, suggesting its potential role in treating hospital-acquired infections caused by these pathogens.
